Headquartered in the UK, and with laboratories in both the UK and France, Reach Separations specializes in chromatography for the analysis and purification of chiral and achiral therapeutics. The company can conduct purification projects from discovery chromatography through to large scale supercritical fluid chromatography (SFC) for chiral purification and impurity isolation.

With the acquisition of Reach, CatSci will be able to offer its global customers holistic chromatographic services for the analysis of small molecules, oligonucleotides and other complex synthetic medicines, the company said.

Ross Burn, CEO of CatSci, commented: “We are excited to welcome Reach Separations into the CatSci Group. The need for solving complex analytical problems while meeting the ever-evolving regulatory demands is growing alongside the development of new modalities, such as oligonucleotides, TACs (Targeting Chimeras), and glues.”

Peter Ridgway, business development director at Reach Separations, added: “Becoming part of the CatSci Group will enhance and strengthen Reach Separations’ ability to deliver excellence in chromatography. Integrating our technologies and expertise across the discovery and development landscape will provide a one-stop-shop for analysis and purification, giving the client a variety of options to progress the journey of their asset.”